BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 12958606)

  • 1. Anti-heavy-chain monoclonal antibodies directed to the acidic regions of the factor VIII molecule inhibit the binding of factor VIII to phospholipids and von Willebrand factor.
    Raut S; Villard S; Grailly S; Gilles JG; Granier C; Saint-Remy JM; Barrowcliffe TW
    Thromb Haemost; 2003 Sep; 90(3):385-97. PubMed ID: 12958606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterisation of an antibody specific for coagulation factor VIII that enhances factor VIII activity.
    Takeyama M; Nogami K; Matsumoto T; Soeda T; Suzuki T; Hattori K; Shima M
    Thromb Haemost; 2010 Jan; 103(1):94-102. PubMed ID: 20062922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A monoclonal antibody to factor VIII inhibits von Willebrand factor binding and thrombin cleavage.
    Precup JW; Kline BC; Fass DN
    Blood; 1991 May; 77(9):1929-36. PubMed ID: 1902121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
    Yada K; Nogami K; Shima M
    Br J Haematol; 2013 Oct; 163(1):104-11. PubMed ID: 23889549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.
    Saenko EL; Shima M; Gilbert GE; Scandella D
    J Biol Chem; 1996 Nov; 271(44):27424-31. PubMed ID: 8910322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A synthetic factor VIII peptide of eight amino acid residues (1677-1684) contains the binding region of an anti-factor VIII antibody which inhibits the binding of factor VIII to von Willebrand factor.
    Foster PA; Fulcher CA; Houghten RA; Zimmerman TS
    Thromb Haemost; 1990 Jun; 63(3):403-6. PubMed ID: 2119526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine.
    Shima M; Scandella D; Yoshioka A; Nakai H; Tanaka I; Kamisue S; Terada S; Fukui H
    Thromb Haemost; 1993 Mar; 69(3):240-6. PubMed ID: 7682339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human factor VIII inhibitor alloantibodies with a C2 epitope inhibit factor Xa-catalyzed factor VIII activation: a new anti-factor VIII inhibitory mechanism.
    Nogami K; Shima M; Nishiya K; Sakurai Y; Tanaka I; Giddings JC; Saenko EL; Yoshioka A
    Thromb Haemost; 2002 Mar; 87(3):459-65. PubMed ID: 11916079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of human B domain-specific anti-factor VIII monoclonal antibodies generated in transgenic mice.
    Lavigne-Lissalde G; Lacroix-Desmazes S; Wootla B; Tarrade C; Schved JF; Kaveri SV; Granier C; Villard-Saussine S
    Thromb Haemost; 2007 Jul; 98(1):138-47. PubMed ID: 17598006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A role for the C2 domain of factor VIII in binding to von Willebrand factor.
    Saenko EL; Shima M; Rajalakshmi KJ; Scandella D
    J Biol Chem; 1994 Apr; 269(15):11601-5. PubMed ID: 7512568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.
    Meeks SL; Healey JF; Parker ET; Barrow RT; Lollar P
    Blood; 2007 Dec; 110(13):4234-42. PubMed ID: 17848617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor.
    Saenko EL; Scandella D
    J Biol Chem; 1995 Jun; 270(23):13826-33. PubMed ID: 7775440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
    Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
    Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitope specificity of anti-FVIII antibodies during immune tolerance therapy with factor VIII preparation containing von Willebrand factor.
    Kallas A; Pooga M; Benhida A; Jacquemin M; Saint-Remy JM
    Thromb Res; 2002 Sep; 107(6):291-302. PubMed ID: 12565716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
    Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
    J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor.
    Saenko EL; Scandella D
    J Biol Chem; 1997 Jul; 272(29):18007-14. PubMed ID: 9218428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A monoclonal antibody (NMC-VIII/10) to factor VIII light chain recognizing Glu1675-Glu1684 inhibits factor VIII binding to endogenous von Willebrand factor in human umbilical vein endothelial cells.
    Shima M; Yoshioka A; Nakajima M; Nakai H; Fukui H
    Br J Haematol; 1992 Aug; 81(4):533-8. PubMed ID: 1390241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes.
    Gilles JG; Lavend'homme R; Peerlinck K; Jacquemin MG; Hoylaerts M; Jorieux S; Mazurier C; Vermylen J; Saint-Remy JM
    Thromb Haemost; 1999 Jul; 82(1):40-5. PubMed ID: 10456452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies against the human factor VIII von Willebrand molecule: characterization and potential for screening of von Willebrand patients.
    Avner P; Arnaud D; Sultan Y; Maisonneuve P; Jeanneau C
    Dev Biol Stand; 1984; 57():69-76. PubMed ID: 6084622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
    Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
    Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.